 SAN DIEGO, April 27, 2021 PRNewswire -- Poseida Therapeutics, Inc. NASDAQ: PSTX, a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced three data presentations to be delivered at the upcoming American Society of Gene and Cell Therapy ASGCT 24th Annual Meeting, being held virtually May 11-14, 2021. Poseida will present the following research at the 2021 ASGCT Annual Meeting: Oral Presentation Title: Preclinical Evaluation of Combined Adeno-Associated Virus and Nanoparticle Delivery of piggyBac Transposon System for Durable Transgene Expression in the Growing Neonatal Murine Liver Session DateTime: Tuesday, May 11, 2021, 5:45pm - 6:00pm ET Abstract Number: 30 Poster Presentations Title: P-BCMA-ALLO1 A Fully Allogeneic Stem Cell Memory T Cell T SCM CAR-T Therapy Targeting BCMA for the Treatment of Multiple Myeloma Shows Potent Anti-Tumor Activity Session DateTime: Tuesday, May 11, 2021, 8:00am 10:00am ET Abstract Number: 789 Title: Anti-c-kit CAR-T Cells Afford Effective Eradication of Human AML and Normal Hematopoietic Cells in a Preclinical Model of Safer Non-Genotoxic Stem Cell Transplant Conditioning Session DateTime: Tuesday, May 11, 2021, 8:00am 10:00am ET Abstract Number: 715 About Poseida Therapeutics, Inc. Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. 